ArticleHuman genomics2026
Promoter landscape of maternal plasma DNA reveals predictive signatures of fetal growth restriction.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFetal growth restriction (FGR) causes serious pregnancy complications, but early detection is challenging. Promoter coverage patterns from maternal plasma cell-free DNA (cfDNA) offer a promising, non-invasive method for early FGR detection.
methodsThis retrospective multicenter study enrolled 788 singleton pregnancies (282 FGR and 506 matched controls) undergoing NIPT blood draw between 12 and 29 weeks of gestation from four hospitals in China. cfDNA promoter coverage was analyzed to identify transcription start site (TSS) features differentially covered in FGR. Feature selection was performed using LASSO regression. Three machine learning models—support vector machine (SVM), logistic regression (LR), and K-nearest neighbor (KNN)—were constructed. Model performance was assessed using area under the ROC curve (AUC), with an internal dataset used for validation. Functional enrichment analysis was conducted for biological interpretation.
resultsA total of 198 differentially covered TSS features were selected. In the validation dataset, both LR and SVM models demonstrated comparable predictive accuracy, with AUCs of 0.7 for LR and 0.69 for SVM. The associated genes were enriched in pathways related to placental and fetal development.
conclusionPromoter profiling of maternal plasma cfDNA represents a novel, non-invasive approach for mid-pregnancy FGR prediction. This method could enhance early detection of at-risk pregnancies and inform clinical decision-making in prenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.